National and Kapodistrian University of Athens
Ανίχνευση μεταλλάξεων του γονιδίου FLT3 στη οξεία μυελογενή λευχαιμία
Abstract
dc:descriptionAcute myeloid leukemia is a morphologically and genetically heterogeneous disease, characterized by rapid proliferation of immature myeloid progenitors cells that gradually displace normal hematopoietic cells. The incidence of AML is approximately 2 to 3 cases per 100.000 persons each year and rises rapidly after 50 years of age to reach a peak of 35/100.000 in persons of 90 years old. Efforts are made to identify prognostic factors that can distinguish cases with adverse or favorable prognosis so patients can be treated accordingly. Currently cytogenetic analysis performed at diagnosis is used to stratify AML patients to favorable, intermediate and adverse prognosis and provides an important tool for selection of therapy. About 50% of newly diagnosed patients have normal cytogenetics-intermediate risk- and in this group of patients there is extreme heterogeneity concerning the outcome after standard treatment. Age is also an adverse prognostic factor with patients over 60 years old experiencing short survival. The cause of this adverse outcome seems to be chemotherapy toxicity, previous myelodysplastic syndrome and adverse cytogenetics. Myelodysplastic syndromes are clonal stem-cell disorders characterized by ineffective hematopoiesis, dysplasia and variable risk of transformation to AML. The etiology of MDS is unknown. The heterogeneity of clinical, morphologic, biologic, and genetic characteristics of MDS has led to evolving classification systems and continuing research proposed to elucidate its pathobiology and disease mechanism. Disease outcome ranges from an indolent course that may span years, to a rapid leukemic progression within several months. MDS therefore represent an excellent model of leukemic development with a progressive increase of blastic bone marrow involvement, but genetic events that lead to this evolution are still not identified. FLT3 gene is located at 13q12 and encodes a transmembrane protein which functions as a receptor on the cell surface. FLT3 protein consists of 993 amino acids: an extracellular region (EC), a transmembrane domain (TM), a juxtamembrane domain, 2 tyrosine kinase domains (TK1 and TK2) and a C-terminal region. Internal tandem duplications (ITD) affecting a segment of the JM domain-coding sequence (exons 14 and 15) were initially described in 20-25% of AML patients and are associated with poor prognosis. Point mutations within the tyrosine kinase domains (FLT3/TKD), mainly within the tyrosine kinase 2 at codon 835 in exon 20, called Asp835, have been found in 5-7% of AML patients. In total, FLT3 mutations (ITD and TKD) have been found in 25-30% of AML patients. These mutations have also been described in about 5% of MDS patients at initial presentation, but their prognostic significance have not been fully assessed. In the current study we found FLT3 mutations in 8 of 44 AML patients (18,2 %) at presentation, aged less than 60 years old. Eighteen patients relapsed and of these patients 8 had FLT3 ITD mutations at the time of relapse (44,4%), while of the 12 patients with intermediate risk cytogenetics that relapsed 7 carried FLT3-ITD at the time of relapse (58,3%). Only one patient that carried FLT3 ITD mutation is alive, in complete remission 10 years. Thirteen of the 40 patients older than 60 had FLT3 mutations at the time of diagnosis (32,5%). Seven patients died during induction and six of these patients carried FLT3 mutations: 4 patients had ITD and 2 patients had both mutations (ITD and Asp835). FLT3 mutations is an independent prognostic factor of AML patients younger than 60 years old. In the current study we show the adverse prognostic impact of these mutations in AML patients aged less than 60, but also in older patients. In the latter patient cohort we observed a high incidence of induction deaths. We also found FLT3 mutations (ITD and Asp835) in 3 of the 97 (3,1%) MDS patients at initial diagnosis. These patients progressed to AML in 2 to 8 months, carrying the same FLT3 mutation that they had at the time of diagnosis of MDS. We also found 3 additional patients with FLT3/ITD mutations during progression to AML. These patients had detectable FLT3 mutations in bone marrow samples 1 month before overt leukemic transformation and it seems that these mutations may be the crucial additional genetic alteration for AML transformation. FLT3 mutations were detected in 2 of the 55 MDS patients who did not transform to AML. Both patients did not carry FLT3 mutations at diagnosis but died from sepsis 2 and 6 months after the detection of FLT3 mutations.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2007
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Georgiou, Georgios
- Γεωργίου, Γεώργιος
Subjects
dc:subject × 11Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/22091